Brief Communication abstract
Nature Neuroscience 10, 411 - 413 (2007)
Published online: 25 February 2007 | doi:10.1038/nn1860
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome
Fabian Fernandez1, Wade Morishita1, Elizabeth Zuniga1, James Nguyen1, Martina Blank1, Robert C Malenka1 & Craig C Garner1
Ts65Dn mice, a model for Down syndrome, have excessive inhibition in the dentate gyrus, a condition that could compromise synaptic plasticity and mnemonic processing. We show that chronic systemic treatment of these mice with GABAA antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation. These results suggest that over-inhibition contributes to intellectual disabilities associated with Down syndrome and that GABAA antagonists may be useful therapeutic agents for this disorder.
- Department of Psychiatry and Behavioral Sciences, Nancy Pritzker Laboratory, Stanford University, Palo Alto, California 94304-5485, USA.
Correspondence to: Craig C Garner1 e-mail: cgarner@stanford.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Brief exposure to hyperoxia depletes the glial progenitor pool and impairs functional recovery after hypoxic-ischemic brain injuryJournal of Cerebral Blood Flow & Metabolism Original Article
High-throughput screening of novel antagonists on melanin-concentrating hormone receptor-1Acta Pharmacologica Sinica Original Article
